Trial Profile
A Phase II multicenter trial of Gemcitabine in combination with R1415 (erlotinibhydrochloride) in patients with unresectable pancreatic cancer (locally advanced or metastatic)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 24 May 2016 New trial record